Role of advanced glycation end products and its receptors in the pathogenesis of cigarette smoke-induced cardiovascular disease

International Journal of Angiology

Volumn 24, Issue 2, 2015, Pages 75-80

  Prasad, Kailash ^a   Dhar, Indu ^a   Caspar Bell, Gudrun ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

advanced glycation end products; cardiovascular disease; cigarette smokers; receptor for AGE; soluble receptors for AGEs

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CELL ADHESION MOLECULE; CIGARETTE SMOKE; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; XANTHINE OXIDASE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; SMOKING;

EID: 84930317067     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0034-1396413     Document Type: Review

References (70)

1. Ockene I. S., Miller N. H.; American Heart Association Task Force on Risk Reduction. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. Circulation: 1997; 96 9 3243 3247
2. Price J. F., Mowbray P. I., Lee A. J., Rumley A., Lowe G. D., Fowkes F. G. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J: 1999; 20 5 344 353
3. Black H. R. Smoking and cardiovascular disease. In: Laragh J. H., Brenner B. M., eds. Hypertension: Pathophysiology, Diagnosis and management. 2nd ed. New York, NY Raven Press Ltd: 1995; 2621 2647
4. Ambrose J. A., Barua R. S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol: 2004; 43 10 1731 1737
5. Negri E., Franzosi M. G., La Vecchia C., Santoro L., Nobili A., Tognoni G.; GISSI-EFRIM Investigators. Tar yield of cigarettes and risk of acute myocardial infarction. BMJ: 1993; 306 6892 1567 1570
6. Jonas M. A., Oates J. A., Ockene J. K., Hennekens C. H.; American Heart Association. Statement on smoking and cardiovascular disease for health care professionals. Circulation: 1992; 86 5 1664 1669
7. Barnoya J., Glantz S. A. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation: 2005; 111 20 2684 2698
8. Herbert W. H. Cigarette smoking and arteriographically demonstrable coronary artery disease. Chest: 1975; 67 1 49 52
9. Waters D., Lespérance J., Gladstone P., et al. CCAIT Study Group. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation: 1996; 94 4 614 621
10. Office of the Surgeon General (US), Office on Smoking and Health (US) The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention. Circulation: 2005; 111 20 2684 2698
11. Benowitz N. L. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis: 2003; 46 1 91 111
12. U.S Department of Health and Human Services The Health benefits of Smoking cessation: A Report of the Surgeon General, DHHS Publication No. (CDC) 90-8416. Rockville, MD U.S Department of Health and Human Services, Public health Services, Centers for Disease Control and Prevention: 1990
13. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation: 1999; 99 10 1355 1362
14. Prasad K., Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis: 2007; 192 2 313 322
15. Pryor W. A., Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci: 1993; 686 12 27, discussion 27-28
16. Smith C. J., Fischer T. H. Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis: 2001; 158 2 257 267
17. Barua R. S., Ambrose J. A., Srivastava S., DeVoe M. C., Eales-Reynolds L. J. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation: 2003; 107 18 2342 2347
18. Srivastava S. K., Barua R. S., Saha D. C., Eales-Reynolds L. J., DeVoe M. C., Ambrose J. A. Endogenous free radical generating source are involved in smoking-mediated dysfunction of nitric oxide biosynthesis in human coronary artery endothelial cells: an in vitro demonstration. (abstr). J Am Coll Cardiol: 2003; 41 (Suppl A) 306A
19. Kayyali U. S., Budhiraja R., Pennella C. M., et al. Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicol Appl Pharmacol: 2003; 188 1 59 68
20. Guthikonda S., Sinkey C., Barenz T., Haynes W. G. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation: 2003; 107 3 416 421
21. Kalra J., Chaudhary A. K., Prasad K. Increased production of oxygen free radicals in cigarette smokers. Int J Exp Pathol: 1991; 72 1 1 7
22. Falcone C., Emanuele E., D'Angelo A., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol: 2005; 25 5 1032 1037
23. Lindsey J. B., de Lemos J. A., Cipollone F., et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care: 2009; 32 7 1218 1220
24. Hudson B. I., Moon Y. P., Kalea A. Z., et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis: 2011; 216 1 192 198
25. McNair E. D., Wells C. R., Qureshi A. M., et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol: 2009; 18 4 187 192
26. McNair E. D., Wells C. R., Mabood Qureshi A., et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol: 2010; 33 11 678 685
27. Basta G., Berti S., Cocci F., et al. Plasma N-epsilon-(carboxymethyl)lysine levels are associated with the extent of vessel injury after coronary arterial stenting. Coron Artery Dis: 2008; 19 5 299 305
28. Park L., Raman K. G., Lee K. J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med: 1998; 4 9 1025 1031
29. Sakaguchi T., Yan S. F., Yan S. D., et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest: 2003; 111 7 959 972
30. Bucciarelli L. G., Wendt T., Qu W., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation: 2002; 106 22 2827 2835
31. Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol: 2006; 15 57 68
32. Schmidt A. M., Yan S. D., Yan S. F., Stern D. M. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta: 2000; 1498 2-3 99 111
33. Bierhaus A., Hofmann M. A., Ziegler R., Nawroth P. P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res: 1998; 37 3 586 600
34. Tam X. HL, Shiu S. WM, Leng L., Bucala R., Betteridge D. J., Tan K. CB. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond): 2011; 120 2 81 89
35. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J: 2003; 370 Pt 3 1097 1109
36. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol: 2005; 25 12 2587 2593
37. Schmidt A. M., Yan S. D., Wautier J. L., Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res: 1999; 84 5 489 497
38. Cerami C., Founds H., Nicholl I., et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A: 1997; 94 25 13915 13920
39. Nicholl I. D., Bucala R. Advanced glycation endproducts and cigarette smoking. Cell Mol Biol (Noisy-le-grand): 1998; 44 7 1025 1033
40. Radoi V., Lixandru D., Mohora M., Vîrgolici B. Advanced glycation end products in diabetes mellitus: mechanism of action and focused treatment. Proc Rom Acad, Series B.: 2012; 1 9 19
41. Berg T. J., Snorgaard O., Faber J., et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care: 1999; 22 7 1186 1190
42. Nicholl I. D., Stitt A. W., Moore J. E., Ritchie A. J., Archer D. B., Bucala R. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med: 1998; 4 9 594 601
43. Gopal P., Reynaert N. L., Scheijen J. L., et al. Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD. Respir Res: 2014; 15 24
44. Iwamoto H., Gao J., Pulkkinen V., Toljamo T., Nieminen P., Mazur W. Soluble receptor for advanced glycation end-products and progression of airway disease. BMC Pulm Med: 2014; 14 68
45. Yokota C., Minematsu K., Tomii Y., et al. Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients. J Neurol Sci: 2009; 287 1-2 41 44
46. Biswas S. K., Mudi S. R., Mollah F. H., Bierhaus A., Arslan M. I. Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects. Diab Vasc Dis Res: 2013; 10 4 380 382
47. Smith D. J., Yerkovich S. T., Towers M. A., Carroll M. L., Thomas R., Upham J. W. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J: 2011; 37 3 516 522
48. Braquet P., Hosford D., Braquet M., Bourgain R., Bussolino F. Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol: 1989; 88 1-2 88 100
49. Yuo A., Kitagawa S., Kasahara T., Matsushima K., Saito M., Takaku F. Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors. Blood: 1991; 78 10 2708 2714
50. Ellis T. N., Beaman B. L. Interferon-gamma activation of polymorphonuclear neutrophil function. Immunology: 2004; 112 1 2 12
51. Watson D. A., Musher D. M., Hamill R. J. Interferon-gamma and polymorphonuclear leukocytes. Ann Intern Med: 1988; 109 3 250 251
52. Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation: 1991; 84 3 1420 1425
53. Prasad K. Textbook of Angiology. In: John B Chang, Earl R Olsen, Kailash Prasad, Bauer E Sumpio, eds. Pathophysiology of Atherosclerosis. New York, NY Springer-Verlag: 2000; 85 105
54. Martin A., Foxall T., Blumberg J. B., Meydani M. Vitamin E inhibits low-density lipoprotein-induced adhesion of monocytes to human aortic endothelial cells in vitro. Arterioscler Thromb Vasc Biol: 1997; 17 3 429 436
55. Faruqi R., de la Motte C., DiCorleto P. E. Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest: 1994; 94 2 592 600
56. Devaraj S., Li D., Jialal I. The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium. J Clin Invest: 1996; 98 3 756 763
57. Keaney J. F. Jr, Gaziano J. M., Xu A., et al. Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest: 1994; 93 2 844 851
58. Nakamura K., Yamagishi S., Adachi H., et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med: 2007; 13 3-4 185 189
59. Pullerits R., Brisslert M., Jonsson I. M., Tarkowski A. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum: 2006; 54 12 3898 3907
60. Fujisawa K., Katakami N., Kaneto H., et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis: 2013; 227 2 425 428
61. Tan K. CB, Shiu S. WM, Chow W. S., Leng L., Bucala R., Betteridge D. J. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia: 2006; 49 11 2756 2762
62. Challier M., Jacqueminet S., Benabdesselam O., Grimaldi A., Beaudeux J. L. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem: 2005; 51 9 1749 1750
63. Basta G., Leonardis D., Mallamaci F., et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int: 2010; 77 3 225 231
64. Hammady M. R., Khashali S. EL, Halim H. A., Rashed L., Hussein M. Soluble receptor for advanced glycation end products (sRAGE) in non-diabetic hemodialysis patients and chronic kidney disease. Med J Cairo Univ: 2012; 80 9 75
65. Tan K. C., Chow W. S., Tam S., Bucala R., Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care: 2004; 27 1 223 228
66. Berg T. J., Dahl-Jorgensen K., Torjesen P. A., Hanssen K. F. Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM. Diabetes Care: 1997; 20 6 1006 1008
67. Kilhovd B. K., Berg T. J., Birkeland K. I., Thorsby P., Hanssen K. F. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care: 1999; 22 9 1543 1548
68. Raj D. S., Choudhury D., Welbourne T. C., Levi M. Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis: 2000; 35 3 365 380
69. Papanastasiou P., Grass L., Rodela H., Patrikarea A., Oreopoulos D., Diamandis E. P. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int: 1994; 46 1 216 222
70. Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease states: Myth or reality. Int J Angiol: 2014; 23 11 16